- News article
Companies call for more hands-on regulatory guidance

Following several inspections of medical software providers, the Norwegian Medical Products Agency (DMP) is strengthening its guidance and planning a dedicated regulatory fast track for AI. At the same time, NorTrials has launched a national guide for medical devices. Both initiatives address some of the needs highlighted by Norway Health Tech members in a recent survey: more practical and accessible regulatory guidance.

Written by
Therese Oppegaard
The Norwegian Medical Products Agency (DMP) has in recent years prioritised software and artificial intelligence as medical devices in its market surveillance activities. Inspections have identified manufacturers that were unaware that their software qualified as a medical device, products that had been classified too low, and cases where, according to DMP, manufacturers had attempted to circumvent the regulations. It is the manufacturer’s responsibility to determine whether a solution qualifies as a medical device and which risk class it belongs to. For companies developing AI solutions, it can be challenging to know where the boundaries lie. Is the solution a medical device? Which risk class does it fall into? What documentation is required? And what are the regulatory implications when an AI model is further developed? Norway Health Tech has called for greater clarity on these issues, which prompted a survey conducted by the cluster in collaboration with DMP.
Calls for more one-to-one guidance
The survey responses point to a particular need for one-to-one guidance early in the development process. Companies are also calling for checklists, opportunities to learn from the experience of other companies, and access to expertise when making key decisions about their overall regulatory strategy.
One respondent states:
“One-to-one guidance is extremely valuable! [...] But it needs to be substantive, not simply point us towards MDR articles and annexes. We can find those ourselves.” (Survey respondent)
Companies are also calling for practical, product-specific guidance on the requirements for AI-based medical devices, particularly regarding clinical documentation and changes to existing products. Several respondents would also like to see concrete examples of how the regulations should be interpreted in practice, for example through a case library.
The Norwegian Medical Products Agency (DMP) recently announced that it will strengthen its guidance for companies developing AI and software as medical devices.
– For many developers of AI-based medical devices, having to navigate the European regulatory framework is new. We understand that this is challenging. It can be difficult to determine when something being developed qualifies as a medical device and which risk class it should fall into, says Helga Brøgger, Senior Adviser at DMP, to MedWatch.
DMP is also developing a new regulatory fast track that will provide selected companies with closer guidance.
– The fast track is inspired by similar schemes in other countries. We aim to have the new scheme ready next year, and we are in dialogue with organisations that support health technology research and development, health clusters and accelerators,” Brøgger says. (Medwatch)
NorTrials launches national guide for medical devices in hospitals
NorTrials has recently launched a national guide for the development and clinical testing of medical devices in Norwegian hospitals. The guide brings the entire process together in one structured pathway, taking users step by step from the initial idea through development and clinical testing to implementation in clinical practice. The aim is to make the journey from idea to patient benefit simpler, more predictable and more accessible for those developing new solutions for the healthcare service.
The guide is aimed particularly at start-ups, but also at established medtech and e-health companies, researchers and clinicians, as well as hospital teams working with innovation, research and procurement. It also covers medical device software, including solutions based on artificial intelligence.
The guide is intended to complement, rather than replace, the MDR and European guidance. It provides a practical Norwegian roadmap for navigating the journey from idea and development to clinical testing and implementation.







